Cardiovascular Business: Flurpiridaz Will Have a Major Impact on Cardiac PET and Nuclear Imaging

Flurpiridaz, a novel positron emission tomography (PET) cardiac radiotracer is poised to make a major impact on nuclear cardiology. Experts in cardiac imaging say it offers much better imaging than the current cardiac nuclear imaging workforce technology.

The results of the flurpiridaz FDA pivotal trial, AURORA were published Oct. 9 in the Journal of the American College of Cardiology. The results showed flurpiridaz significantly exceeded prespecified threshold criteria for the detection of CAD and was superior to Tc-labeled SPECT MPI for the detection of CAD in the overall population and in women and obese patients.

These findings have paved the way for the anticipated approval of flurpiridaz by the U.S. Food and Drug Administration (FDA). GE Healthcare, the manufacturer of flurpiridaz, has submitted the results to the FDA for final review.

Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute and co-author on the AURORA study, spoke with Cardiovascular Business about his group's findings and what it is like to work with flurpiridaz.

Read the full Cardiovascular Business article: Flurpiridaz Will Have a Major Impact on Cardiac PET and Nuclear Imaging